Misleading claims, outdated formulas: Most sunscreens fail to fully protect, report says
The Environmental Working Group published its 2025 Annual Guide to Sunscreens, finding that fewer than one in four SPF products met its criteria. The health research organization evaluated more than 2,200 products and found that fewer than 500 effectively protect a user's skin.
The report also shared insight into what it says are shortfalls within federal sunscreen regulations and the deceptive marketing practices by corporations.
"Many sunscreens still fall short by offering misleading claims about protection, using outdated formulas, some even containing ingredients with potential health concerns," the 2025 guide says. "Federal sunscreen rules have remained largely unchanged since 1999, leaving consumers to navigate products with uncertainty."
In 2019, the U.S. Food and Drug Administration proposed new aerosol-testing requirements for spray sunscreens to address concerns of inhalation risks and uneven application but never finalized them, according to the report.
Despite sprays representing 26% of all SPF products in 2025, the report warns the inhalation risk is still prevalent. There were multiple recalls regarding benzene contamination between 2021 to 2023.
The report also warned against products with an undisclosed "fragrance," revealing that 36% of said products this year included allergens, hormone disruptors and carcinogens.
In 2022, a federal law required the FDA to develop guidelines for disclosing fragrance allergens in certain SPF products by July 2024, the report stated. Yet no proposal has been shared as of May, with the Environmental Working Group warning that recent staffing shortages enforced by the Trump Administration may further slow the process.
The FDA did not immediately respond to USA TODAY's request for comment late Tuesday.
"In the meantime, (the Environmental Working Group) continues to urge consumers to choose fragrance-free sunscreens or those carrying the EWG Verified® mark, which guarantees ingredient transparency and the absence of harmful fragrance chemicals," the guide reads.
The report also noted a decline in sunscreen products that contain oxybenzone and Vitamin A, amid growing awareness surrounding the safety and effectiveness of both.
The high-skin absorption of oxybenzone in non-mineral sunscreens poses several health concerns like hormones disruption and is harmful for aquatic and marine ecosystems, the report stated. In 2016, oxybenzone was used in 70% of non-mineral sunscreens. Now that number is at 9%.
Research shows that Vitamin A in SPF products can degrade in sunlight, possibly worsening skin damage more than not wearing sunscreen, according to the working group. Only 2% of SPF products currently contain Vitamin A, typically in the form of retinyl palmitate, a significant decline compared to 41% in 2010.
The 2025 Annual Guide to Sunscreens report offered the following advice for sunscreen users hoping to stay safe from harmful sun rays and avoid the risk of skin cancer.
Don't fall for high SPF labels
Remember to reapply often
Choose lotions and sticks over sprays
Avoid ingredients of concern and look for mineral products with zinc oxide
Use EWG's list of top-rated sunscreens and the EWG Verified mark to find the products that work best for you
Wear clothing, hats, and sunglasses for additional sun protection
Avoid the sun during peak hours (typically 10 a.m. to 4 p.m.)
Protect kids, whose skin is especially sensitive to UV damage
Be cautious around water and sand, which reflect UV rays and increase exposure
Check the UV index in your area for real-time guidance on sun safety
To see the entire 2025 Annual Guide to Sunscreens report, click here.
This article originally appeared on USA TODAY: Fewer than 1 in 4 sunscreen products are fully safe, effective: Report
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth
We recently published . GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best healthcare stocks. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading U.S. digital healthcare platform that helps consumers compare prescription drug prices and access discounts, while also expanding into telehealth and other healthcare services. A major recent focus is the company's growth in pharma manufacturer solutions, where it partners with drug makers for targeted advertising and patient access programs. In Q2 2025, revenue from this segment rose 32%, prompting GoodRx to raise its full-year growth forecast from 20% to 30%. This shift diversifies its business beyond traditional prescription savings cards and strengthens its role as a key marketing partner for pharmaceutical companies. Copyright: zneb076 / 123RF Stock Photo GoodRx Holdings, Inc. (NASDAQ:GDRX) is also broadening its consumer offerings through subscription-based services, including a new program for affordable erectile dysfunction medications (Sildenafil and Tadalafil). These initiatives support its mission of lowering out-of-pocket drug costs while enhancing direct-to-consumer healthcare access. Its telehealth platform remains an important but underutilized growth channel, with potential for further expansion. Additionally, GoodRx Holdings, Inc. (NASDAQ:GDRX) is undergoing a brand relaunch and implementing targeted marketing strategies to boost engagement and market share. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion
We recently published . LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the best healthcare stocks. LifeStance Health Group, Inc. (NASDAQ:LFST) stands fifth among the best healthcare stocks. It is one of the largest outpatient mental health providers in the U.S. that operates over 550 locations across 33 states with nearly 7,500 clinicians, offering a hybrid of in-person and telehealth care (about 70% virtual). The company primarily serves patients with commercial insurance and focuses on expanding access to affordable behavioral health services. In 2025, LifeStance Health Group, Inc. (NASDAQ:LFST) accelerated its digital transformation, with a strong emphasis on artificial intelligence (AI) to improve efficiency. AI tools are being deployed in revenue cycle management, patient scheduling, and soon, clinician documentation, aimed at reducing administrative burdens and improving satisfaction. The appointment of Vaughn Paunovich as CTO marks a renewed push toward technology-driven operations. As part of this effort, the business is reviewing new electronic health record (EHR) platforms, with a decision expected by late 2025. Operational upgrades also include a digital patient check-in tool, improved HR and credentialing systems, and enhanced payer engagement platforms. These changes are designed to strengthen operational foundations for sustainable growth rather than rapid, acquisition-heavy expansion. Copyright: racorn / 123RF Stock Photo Q2 2025 saw an 11% increase in clinicians (173 added), supported by scheduling and productivity technologies that have improved retention and patient management. LifeStance Health Group, Inc. (NASDAQ:LFST) expects these digital and AI investments to yield significant productivity gains and improved patient care from 2026 onward, positioning the company as a leader in next-generation, tech-enabled mental health services. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published . MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks. Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025. Copyright: nicoletaionescu / 123RF Stock Photo To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.